Florfenicol is a synthetic broad-spectrum antibiotic that is structurally related to thiamphenicol. It is effective against a wide range of gram-negative and gram-positive bacteria, including those that are resistant to other antibiotics. Florfenicol is used to treat bacterial infections in animals, such as bovine respiratory disease, swine dysentery, and fish diseases. It is also used in humans, but only in limited cases. Florfenicol works by inhibiting bacterial protein synthesis. Specifically, it binds to the 50S ribosomal subunit, preventing the formation of peptide bonds and inhibiting the elongation of the polypeptide chain. Florfenicol is well-absorbed after oral administration, and it reaches therapeutic concentrations in most tissues. It is excreted in urine and feces. Florfenicol is a relatively safe drug, but side effects can occur, including gastrointestinal upset, anemia, and hypersensitivity reactions. Research on florfenicol is ongoing, focusing on its efficacy against various bacterial strains, its pharmacokinetic properties, and its potential for developing resistance. Florfenicol is an important antibiotic for treating bacterial infections in animals, but it is important to use it responsibly to prevent the development of resistance.'
florfenicol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 114811 |
| CHEMBL ID | 1241590 |
| CHEBI ID | 87185 |
| SCHEMBL ID | 49425 |
| SCHEMBL ID | 21835523 |
| MeSH ID | M0108821 |
| Synonym |
|---|
| AC-4340 |
| smr001233384 |
| MLS002154071 |
| BRD-K11298197-001-03-9 |
| sch-25298 |
| florfenicol |
| nuflor |
| BPBIO1_001046 |
| d-threo-2,2-dichloro-n-(alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide |
| benzenesulfonic acid, 4-(2-((dichloroacetyl)amino)-3-fluoro-1-hydroxypropyl)-, methyl ester, (r-(r*,s*))- |
| florphenicol |
| (-)-florfenicol |
| thiamphenicol, 3-fluoro |
| acetamide, 2,2-dichloro-n-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)-, (r-(r*,s*))- |
| 3-fluorothiamphenicol |
| 2,2-dichloro-n-(1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)acetamide |
| 2,2-dichloro-n-((alphas,betar)-alpha-(fluoromethyl)-beta-hydroxy-p-(methylsulfonyl)phenethyl)acetamide |
| florfenicol [usan:inn:ban] |
| acetamide, 2,2-dichloro-n-((1s,2r)-1-(fluoromethyl)-2-hydroxy-2-(4-(methylsulfonyl)phenyl)ethyl)- |
| c12h14cl2fno4s |
| sch 25298 |
| cas-73231-34-2 |
| NCGC00016922-01 |
| NCGC00179366-01 |
| D04194 |
| 73231-34-2 |
| nuflor (tn) |
| florfenicol (usan/inn) |
| PRESTWICK3_000955 |
| AB00513976 |
| PRESTWICK2_000955 |
| BSPBIO_000950 |
| PRESTWICK1_000955 |
| PRESTWICK0_000955 |
| SPBIO_003099 |
| HMS2090I10 |
| HMS1570P12 |
| 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide |
| A838774 |
| 2,2-dichloro-n-[(1s,2r)-1-(fluoromethyl)-2-hydroxy-2-(4-methylsulfonylphenyl)ethyl]acetamide |
| 76639-94-6 |
| HMS2097P12 |
| 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)-2-propyl]acetamide |
| d-(-)-threo-2-dichloroacetamido-3-fluoro-1-(4-methylsulfonylphenyl)-1-propanol |
| F0811 |
| CHEMBL1241590 |
| chebi:87185 , |
| nsc-759287 |
| dtxsid9045500 , |
| tox21_110683 |
| dtxcid7025500 |
| unii-9j97307y1h |
| 9j97307y1h , |
| nuflor gold |
| nsc 759287 |
| HMS2230K18 |
| S4201 |
| aquafen |
| AKOS015889457 |
| florfenicol [ema epar veterinary] |
| florfenicol [inn] |
| 2,2-dichloro-n-((.alpha.s,.beta.r)-.alpha.-(fluoromethyl)-.beta.-hydroxy-p-(methylsulfonyl)phenethyl)acetamide |
| florfenicol [mart.] |
| florfenicol component of zeleris |
| florfenicol [green book] |
| florfenicol [mi] |
| florfenicol component of osurnia |
| florfenicol [usan] |
| d-threo-2,2-dichloro-n-(.alpha.-(fluoromethyl)-.beta.-hydroxy-p-(methylsulfonyl)phenethyl)acetamide |
| osurnia component florfenicol |
| florfenicol [jan] |
| zeleris component florfenicol |
| CCG-220955 |
| SCHEMBL49425 |
| tox21_110683_1 |
| NCGC00179366-03 |
| KS-5028 |
| (1r,2s)-2-dichloroacetamido-3-fluoro-1-[4-(methylsulfonyl) phenyl]-1-propanol |
| (1r,2s)-2-dichloroacetamido-3-fluoro-1-[4-(methylsulfonyl)phenyl]-1-propanol |
| AYIRNRDRBQJXIF-NXEZZACHSA-N |
| CS-4857 |
| 2,2-dichloro-n-{(1r,2s)-3-fluoro-1-hydroxy-1-[4-(methanesulfonyl)phenyl]propan-2-yl}acetamide |
| HY-B1374 |
| AB00513976_09 |
| mfcd00864834 |
| 2,2-dichloro-n-[(1r,2s)-3-fluoro-1-hydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide |
| florfenicol, analytical standard, for drug analysis |
| NCGC00179366-04 |
| HMS3714P12 |
| SW197224-3 |
| (methylsulfonyl)phenyl)propan-2-yl)acetamide |
| 2,2-dichloro-n-((1r,2s)-3-fluoro-1-hydroxy-1-(4- |
| 2,2-dichloro-n-((1r,2s)-3-fluoro-1-hydroxy-1-(4-(methylsulfonyl)phenyl)propan-2-yl)acetamide |
| (-)-florfenicol;sch-25298 |
| DB11413 |
| 2,2-dichlor-n-((1r,2s)-3-fluor-1-hydroxy- 1-(4-(methylsulfonyl)-phenyl)-propan-2-yl)-ethanamide |
| 2,2-dichloro-n-((1r,2s)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)-2-propyl)acetamide |
| Q408400 |
| 2,2-dichloro-n-[(1r,2r)-3-fluoro-1-hydroxy-1-(4-methylsulfonylphenyl)propan-2-yl]acetamide |
| T72886 |
| SCHEMBL21835523 |
| EN300-7371088 |
| chloramphen |
| BF166386 |
| Z2065671685 |
| florfenicol injection |
| nuflor concentrate solution |
| florfenicolum |
| aquaflortype a medicated article |
| aquaflor type a medicated article |
| norfenicol |
| florcon |
| florvio 2.3% concentrate solution |
| 2,2-dichloro-n-((1r,2s)-3-fluoro-1-hydroxy-1-(4-(methanesulfonyl)phenyl)propan-2-yl)acetamide |
| 2,2-dichloro-n-((alpha s,beta-alpha r)-(fluoromethyl)-beta-hydroxy-4-methanesulfonylphenethyl)acetamide |
| nuflor, nuflor-s |
| florfenicol (ema epar veterinary) |
| nuflor-s |
| nuflorgold |
| florfenicol (mart.) |
| loncor 300 |
Florfenicol is a broad spectrum antibacterial, licensed globally for treatment of animal and aquaculture diseases. Florfenicol (FFC) is a commonly used antibiotic in animal husbandry, which is easy to cause organs damage in a variety of animals.
Florfenicol resistance has emerged over the past few years in multidrug-resistant Salmonella enterica serovars Typhimurium, Agona and Paratyphi B. Florfenicol has been shown to possess anti-inflammatory activity.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Florfenicol (FFC) has been widely used in veterinary clinics for bacterial diseases treatment." | ( Influence of three coccidiostats on the pharmacokinetics of florfenicol in rabbits. Liu, C; Shao, YX; Wang, SJ; Zhang, Q, 2015) | 1.38 |
| "Florfenicol has been shown to possess anti-inflammatory activity. " | ( Florfenicol inhibits allergic airway inflammation in mice by p38 MAPK-mediated phosphorylation of GATA 3. Chi, C; Junqing, C; Xiao, C; Xinxin, C; Xue, X; Xuming, D; Yongjun, Y, 2011) | 3.25 |
| "Florfenicol resistance has emerged over the past few years in multidrug-resistant Salmonella enterica serovars Typhimurium, Agona and Paratyphi B. " | ( Florfenicol resistance in Salmonella enterica serovar Newport mediated by a plasmid related to R55 from Klebsiella pneumoniae. Baucheron, S; Chaslus-Dancla, E; Cloeckaert, A; Martel, JL; Meunier, D, 2003) | 3.2 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Florfenicol-fed fish had lower myeloperoxidase activity at 3 days post-withdrawal, while there were differential effects on alkaline phosphatase activity." | ( In vivo modulation of immune response and antioxidant defense in Atlantic cod, Gadus morhua following oral administration of oxolinic acid and florfenicol. Berg, I; Brinchmann, MF; Caipang, CM; Kiron, V; Lazado, CC, 2009) | 1.28 |
Florfenicol treatment of pigeons via the drinking water from 2 days after experimental inoculation with Salmonella serovar Typhimurium until euthanasia at 16 days postinoculation. Treatment with florfenicol caused a marked reduction in inflammatory cells and three Th2 type cytokines in the bronchoalveolar lavage fluids of mice.
Study evaluated the pharmacokinetic disposition of thiamphenicol (THA) and florfenicol (FLR) after oral administration of each at a single dose of 10 mg/kg body weight in Pacific white shrimp Litopenaeus vannamei held in freshwater at 25.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The purpose of the present clinical studies was to determine the clinical efficacy of a combined parenteral and oral treatment with Bisolvon in combination with antibiotics in bovines suffering from acute respiratory disease." | ( [Treatment of acute respiratory tract diseases in cattle with Bisolvon in combination with either enrofloxacin, cefquinome, ceftiofur or florfenicol]. Hamel, U; Philipp, H; Quirke, JF; Schmidt, H, 1998) | 0.5 |
A study on the bioavailability and pharmacokinetics of florfenicol was conducted in 20 crossbred healthy sheep following a single intravenous (i.v.) injection. The extent of the protein binding and systemic bioavailability were 22.5h, mean residence time was 15 h, mean absorption time was 12h and absolute bioavailability of florfe after i.v.
Study assessed safety of oral florfenicol (FFC) dosing at 0-10 times the therapeutic dose (1 × : 10 mg/kg biomass/day) in Oreochromis niloticus juveniles. More research into determination of PK/PD targets of efficacy is needed. Florfenicol was developed as an injectable antibiotic for use in cattle on an every other day dosing schedule.
| Excerpt | Relevance | Reference |
|---|---|---|
| " When a drug product is dosed via drinking water in a farm setting, a number of variables, including pH, chlorine content, hardness of the water used for dilution, and container material, may affect its stability, leading to a decrease in drug potency." | ( Stability of florfenicol in drinking water. Eichman, J; Gilewicz, R; Hayes, JM; Katz, T, ) | 0.5 |
| " Florfenicol was developed as an injectable antibiotic for use in cattle on an every other day dosing schedule." | ( Use of florfenicol in non-human primates. Cook, AL; Sams, R; St Claire, M, 2004) | 1.69 |
| " Five dosage levels of FFC in medicated feed were administered daily: 0, 5, 10, 15, and 30 mg of active ingredient/kg of fish body weight." | ( Laboratory efficacy of florfenicol against Streptococcus iniae infection in sunshine bass. Darwish, AM, 2007) | 0.65 |
| " Further pharmacodynamic studies in quail are needed to evaluate a suitable dosage regimen." | ( Pharmacokinetics of florfenicol in the plasma of Japanese quail. Atila, A; Kadioglu, Y; Koc, F; Ozturk, M; Uney, K, 2009) | 0.68 |
| "A dose titration study was conducted to determine the dosage of florfenicol (FFC) in feed to control Streptococcus iniae-associated mortality in Nile tilapia Oreochromis niloticus." | ( Determination of florfenicol dose rate in feed for control of mortality in Nile tilapia infected with Streptococcus iniae. Baumgartner, W; Camus, A; Endris, R; Gaunt, PS; McGinnis, A; Steadman, J; Sun, F; Sweeney, D, 2010) | 0.94 |
| " Results from these studies support that 10 mg florfenicol/kg body weight in channel catfish is an efficacious dosage following oral administration." | ( Single intravenous and oral dose pharmacokinetics of florfenicol in the channel catfish (Ictalurus punctatus). Adams, P; Crouch, L; Endris, R; Gao, D; Gaunt, PS; Langston, C; Sweeney, D; Wrzesinski, C, 2012) | 0.89 |
| " Dosing to achieve MPC concentrations (where possible) may serve to reduce the selection of bacterial subpopulations with reduced antimicrobial susceptibility." | ( Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica. Blondeau, BJ; Blondeau, JM; Blondeau, LD; Borsos, S; Hesje, CE, 2012) | 0.59 |
| " Feed consumption was only affected during the last 10 dosing days when the 45 and 75 mg/kg groups consumed only 62." | ( Safety of florfenicol administered in feed to tilapia (Oreochromis sp.). Endris, RG; Gaikowski, MP; Schleis, SM; Tuomari, D; Wolf, JC, 2013) | 0.79 |
| " The aim of this study was to evaluate the depletion of florfenicol and its major metabolite, florfenicol amine, from the edible tissue of two fish species, rainbow trout and sea bream, following treatment with medicated feed at a dosage of 10 mg kg(-1) of bw day(-1) , for 10 consecutive days." | ( Florfenicol depletion in edible tissue of rainbow trout, Oncorhynchus mykiss (Walbaum), and sea bream, Sparus aurata L. della Rocca, G; Di Salvo, A; Malvisi, J; Terzetti, E, 2013) | 2.08 |
| " These data form a rational basis for dosage selection for treatment of calf pneumonia caused by M haemolytica or P multocida." | ( Pharmacodynamics of florfenicol for calf pneumonia pathogens. Cheng, Z; Illambas, J; Lees, P; Potter, T; Rycroft, AN; Sidhu, P, 2013) | 0.71 |
| " dosing was 3h." | ( Pharmacokinetics of florfenicol after intravenous and intramuscular dosing in llamas. Lakritz, J; Niehaus, AJ; Pentecost, RL; Werle, NA, 2013) | 0.71 |
| " More research into determination of PK/PD targets of efficacy is needed to further assess the clinical use of chloramphenicol and florfenicol as second-line agents in dogs, optimize dosage regimens, and set up species-specific clinical break points." | ( In vitro assessment of chloramphenicol and florfenicol as second-line antimicrobial agents in dogs. Guardabassi, L; Maaland, MG; Mo, SS; Schwarz, S, 2015) | 0.88 |
| " dosing was also prolonged (p = 0." | ( Absorption and disposition of florfenicol after intravenous, intramuscular and subcutaneous dosing in alpacas. Lakritz, J; Niehaus, AJ; Pentecost, RL; Werle, N, 2015) | 0.71 |
| " The results demonstrated that the in situ forming gel system could shorten dosing interval of FFC and thus achieved less frequent administration during long-term treatment." | ( Study of pharmacokinetics of an in situ forming gel system for controlled delivery of florfenicol in pigs. Geng, ZX; Li, HM; Liu, TF; Tian, J; Yu, ZG, 2015) | 0.64 |
| " Several product labels provided inadequate information on how to calculate therapeutic dosage and further stated withdrawal time despite lack of pharmacokinetic data on the antimicrobials in catfish." | ( Quality of Antimicrobial Products Used in Striped Catfish (Pangasianodon hypophthalmus) Aquaculture in Vietnam. Dalsgaard, A; Phu, TM; Phuong, NT; Scippo, ML, 2015) | 0.42 |
| " The effects of pH, pressure and Flo concentration on removal efficiency of NF and the effects of pH, Flo concentration and dosage of hydrogen peroxide and contact time on the AOP are assessed." | ( Treatment of florfenicol of synthetic trout fish farm wastewater through nanofiltration and photocatalyst oxidation. Cheshmberah, F; Esmaili, Z; Farhadian, M; Solaimany Nazar, AR, 2017) | 0.82 |
| " These data indicate the value of using a biological medium, when determining microbiological potency indices, to predict dosage for clinical use." | ( Activity of florfenicol for Actinobacillus pleuropneumoniae and Pasteurella multocida using standardised versus non-standardised methodology. Dorey, L; Hobson, S; Lees, P, 2016) | 0.81 |
| " We characterized the toxicokinetics of FLR in the swimming crab (Portunus trituberculatus) after intravenous (IV) dosing (20, 40 and 80mg/kg)." | ( Effects of florfenicol on the antioxidant status, detoxification system and biomolecule damage in the swimming crab (Portunus trituberculatus). Gao, B; Li, J; Liu, P; Ren, X; Wang, Z, 2017) | 0.84 |
| "Pharmacokinetic-pharmacodynamic (PK/PD) integration and modelling were used to predict dosage schedules for florfenicol for two pig pneumonia pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida." | ( Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida. Cheng, Z; Dorey, L; Lees, P; Pelligand, L, 2017) | 0.91 |
| " The model accurately predicted the concentration-time courses of FF in lung interstitial fluid, serum, and plasma following different dosing schedules, except at the dose of 15 mg/kg." | ( Diffusion-limited PBPK model for predicting pulmonary pharmacokinetics of florfenicol in pig. Gao, JD; Huang, LL; Ke, XB; Qian, MR; Sun, GZ; Wang, QY; Yang, B; Yang, H; Yang, JJ, 2017) | 0.69 |
| "For all organisms and all drugs investigated in this study, it is suggested that broth MICs should be adjusted by an appropriate scaling factor when used to determine pharmacokinetic/pharmacodynamic breakpoints for dosage prediction." | ( Impact of growth matrix on pharmacodynamics of antimicrobial drugs for pig pneumonia pathogens. Dorey, L; Lees, P, 2017) | 0.46 |
| " MPC concentrations provide a dosing target which may serve to reduce amplification of bacterial subpopulations with reduced antimicrobial susceptibility." | ( Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis. Blondeau, JM; Fitch, SD, 2019) | 0.73 |
| " The long-acting injectable preparation of doxycycline was well tolerated by koalas when administered via the subcutaneous route, and the weekly dosing requirement is a major advantage when treating wild animals." | ( Clinical comparison of five anti-chlamydial antibiotics in koalas (Phascolarctos cinereus). Booth, R; Nyari, S, 2020) | 0.56 |
| " Thus, the selected FF and TP dosage may be considered as a safe treatment for geese." | ( Pharmacokinetics of florfenicol and thiamphenicol after single oral and intravenous, as well as multiple oral administrations to geese. Poźniak, B; Smutkiewicz, A; Świtała, M; Tikhomirov, M, 2021) | 0.94 |
| " Fitting with published pharmacokinetic profiles that experimented under temperatures of 22 and 28 °C, a PBPK model was constructed by applying with the Bayesian Markov chain Monte Carol (MCMC) algorithm to estimate WTs under different physiological, environmental and dosing scenarios." | ( Bayesian population physiologically-based pharmacokinetic model for robustness evaluation of withdrawal time in tilapia aquaculture administrated to florfenicol. Chen, WY; Lin, HC, 2021) | 0.82 |
| " Whether or not the numbers and extent of PK parameters change mitigate subsequent estimations of other PK-derived secondary values such as dosing regimen and withdrawal time remains to be elucidated, but the auxiliary use of anaesthetics in PK studies should not assume uninfluential." | ( Differential effects of aquatic anaesthetics on the pharmacokinetics of antibiotics: Examples using florfenicol in Nile tilapia (Oreochromis niloticus). Chang, SK; Chi, Y; Chou, CC; Chuchird, N; Hsieh, CY; Rairat, T, 2021) | 0.84 |
| " This study assessed the safety of 30 days of oral florfenicol (FFC) dosing at 0-10 times the therapeutic dose (1 × : 10 mg/kg biomass/day) in Oreochromis niloticus juveniles." | ( The effects of extended feeding of florfenicol coated medicated diets on the safety, serum biomarkers and blood cells morphology of Nile tilapia Oreochromis niloticus (L.). Abraham, TJ; Bardhan, A; Patil, PK; Saha, S; Sarker, S; Singha, J, 2022) | 1.25 |
| " Overall, FF absorption, distribution, and elimination rates were reduced by starvation, resulting in four to five times lower optimal dosage than the non-starved fish." | ( Effects of starvation on the pharmacokinetics and optimal dosages of florfenicol and associated serum biochemistry in Asian seabass (Lates calcarifer). Chou, CC; Ho, WC; Hsieh, MK; Lu, YP; Rairat, T; Wu, HC, 2023) | 1.14 |
| "v bolus of florfenicol solution and dosed orally with FSRGs in the fasting and fed states." | ( Florfenicol sustained-release granules: an in vitro-in vivo correlation study in pigs. Huang, XH; Liu, ZY; Shen, Y; Xu, Y; Yang, WC; Yu, Y; Zhang, YX, 2023) | 2.74 |
| Role | Description |
|---|---|
| antimicrobial agent | A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| sulfone | An organosulfur compound having the structure RS(=O)2R (R =/= H). |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 3.1833 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 0.1188 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 2.9849 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 1.4960 | 0.0015 | 30.6073 | 15,848.9004 | AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 12.0318 | 0.0002 | 29.3054 | 16,493.5996 | AID743091 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 3.5481 | 0.7943 | 21.2757 | 50.1187 | AID624246 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S7 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L15 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L10 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L11 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L19 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L1 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L20 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L27 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L28 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L29 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L31 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L32 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L33 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L34 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L35 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L36 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S10 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S11 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S12 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S13 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S16 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S18 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S19 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S20 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S2 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S3 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S4 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S5 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S8 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S9 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L13 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L14 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L16 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L23 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S15 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L17 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L21 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L30 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L6 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S14 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S17 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S1 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L18 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L2 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L3 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L24 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L4 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L22 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L5 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 30S ribosomal protein S21 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L25 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | IC50 (µMol) | 20.0000 | 0.0089 | 1.2035 | 5.0000 | AID531644 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| twin arginine protein translocation system - TatA protein | Escherichia coli str. K-12 substr. MG1655 | AC50 | 3.8340 | 0.7070 | 10.9151 | 45.8560 | AID504941 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46 | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID520743 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus RN4220 harboring erm(B) and cfr gene assessed as modification of A2503 site in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID584116 | Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP72 | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID572594 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 902SA92 harboring plasmid encoded RamR gene, GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585420 | Antimicrobial activity against oqxAB positive Escherichia coli C600 W191-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID519151 | AUC (0 to infinity) in pigeon at 30 mg/kg, iv by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572818 | Antimicrobial activity against ramR-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID520735 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring erm(B) and cfr gene by disk diffusion assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID519158 | Systemic clearance in pigeon at 30 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID511436 | Antimicrobial activity against multidrug-resistant flogene-deficient Clostridium perfringens LFM1 harboring single C>T at bp 404 of rplD gene | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4. |
| AID519176 | Drug uptake in Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 infected pigeon at 26 to 45 mg/kg | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572813 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/41 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572597 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 102SA00 harboring plasmid encoded RamR gene, GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID584996 | Antibacterial activity against methicillin-resistant Staphylococcus aureus M05/0060 harboring cfr-encoding conjugative pSCFS7 and fexA by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. |
| AID572805 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519170 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 in pigeon macrophage assessed as decrease in bacterial count at 64 ug/ml after 16 hrs | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID520745 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CM05 assessed as modification of A2503 site in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID584994 | Antibacterial activity against Staphylococcus aureus XU21-T1 harboring cfr-encoding conjugative pSCFS7 and fexA by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. |
| AID563229 | Antimicrobial activity against apramycin-resistant cmlR1 null mutant Streptomyces coelicolor B754 after 48 hrs relative to wild type | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor. |
| AID531638 | Selectivity ratio of IC50 for rabbit reticulocyte 50S ribosomal subunit to IC50 for Staphylococcus aureus ATCC 29213 50S ribosomal subunit | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID531642 | Antimicrobial activity against linezolid-resistant Enterococcus faecalis P5 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID519164 | Oral bioavailability in pigeon at 30 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572808 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/21 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID584995 | Antibacterial activity against pSCFS7-deficient methicillin-resistant Staphylococcus aureus M05/0060-C1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. |
| AID519147 | Clearance in pigeon at 30 mg/kg, iv by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID531644 | Displacement of [3H]chloramphenicol from 70S ribosomal complex in Staphylococcus aureus ATCC 29213 by competitive binding assay | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID572817 | Antimicrobial activity against ramR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585428 | Antimicrobial activity against oqxAB positive Escherichia coli C600 SW8-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID542386 | Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ST9 expressing cfr, fexA and erm(C) genes | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. |
| AID572795 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN9181 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID531637 | Inhibition of 50S ribosomal subunit purified from linezolid-,erythromycin-resistant Staphylococcus aureus A7820 with G2576U mutation in 23s rRNA assessed as inhibition of translation using in vitro transcribed mRNA encoding firefly luciferase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID520739 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring cfr gene with mutagenized second codon CAG | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID572599 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN10055 harboring GyrA S83Y mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID531636 | Inhibition of 50S ribosomal subunit purified from Staphylococcus aureus ATCC 29213 assessed as inhibition of translation using in vitro transcribed mRNA encoding firefly luciferase | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID519171 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 at 2 ug/ml after 16 hrs | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID520733 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid MS2 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID531639 | Antimicrobial activity against Staphylococcus aureus ATCC 29213 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID585430 | Antimicrobial activity against oqxAB positive Escherichia coli C600 SP8-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID660264 | Ratio of MIC for wild type Escherichia coli HS414 to MIC for acrB-deficient Escherichia coli HS832 by agar dilution method | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID572809 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/21 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519159 | Intracompartmental-distribution clearance at 30 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID585425 | Antimicrobial activity against oqxAB positive Escherichia coli C600 G375-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID572814 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/71 harboring GyrA G81C, acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID1873887 | Induction of drug resistance in Escherichia coli ATCC 25922 assessed as increase in MIC measured after 30 passages by broth microdilution method | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives. |
| AID519160 | Volume of distribution in central compartment in pigeon at 30 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID542388 | Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus ST398 plasmid pSCFS3 carrying cfr and fexA genes | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. |
| AID584993 | Antibacterial activity against Staphylococcus aureus XU21 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | Identification and characterization of the multidrug resistance gene cfr in a Panton-Valentine leukocidin-positive sequence type 8 methicillin-resistant Staphylococcus aureus IVa (USA300) isolate. |
| AID572812 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/41 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572800 | Antimicrobial activity against soxR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519150 | Half life at beta phase in pigeon at 30 mg/kg, iv by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID511437 | Antimicrobial activity against flo gene positive Escherichia coli | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4. |
| AID511433 | Antimicrobial activity against Clostridium perfringens LFM1 assessed as resistance breakpoint by DANMAP method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4. |
| AID520738 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring cfr gene with mutagenized first codon CAG | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID519165 | Plasma concentration in pigeon at 0.5 mg/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572786 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN10055 harboring GyrA S83Y mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519155 | Absorption half life in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID511430 | Antimicrobial activity against Clostridium perfringens LFM1 assessed as susceptibility breakpoint by DANMAP method | 2010 | Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3 | Resistance to linezolid in a porcine Clostridium perfringens strain carrying a mutation in the rplD gene encoding the ribosomal protein L4. |
| AID572815 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/71 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572789 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 543SA98 harboring GyrA S83Y mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572810 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/21 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585433 | Antimicrobial activity against Escherichia coli DH5[alpha] by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID585429 | Antimicrobial activity against Escherichia coli C600 ST2-T transconjugant harboring oqxAB, qnrB6 and aac(6')-Ib-cr genes by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID585424 | Antimicrobial activity against oqxAB positive Escherichia coli C600 G062-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID520736 | Antimicrobial activity against erm(B) and cfr-deficient Staphylococcus aureus RN4220 harboring plasmid LI50 by disk diffusion assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID519162 | AUC (0 to infinity) in pigeon at 30 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID519161 | Volume of distribution in peripheral compartment in pigeon at 30 mg/kg, iv | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID519157 | Cmax in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID543237 | Antibacterial activity against multidrug-resistant Salmonella enterica serovar Virchow B100 expressing floR2 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Truncated tni module adjacent to the complex integron of salmonella genomic island 1 in Salmonella enterica serovar Virchow. |
| AID563230 | Antimicrobial activity against apramycin-resistant cmlR2 null mutant Streptomyces coelicolor B756 after 48 hrs relative to wild type | 2009 | Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11 | Two distinct major facilitator superfamily drug efflux pumps mediate chloramphenicol resistance in Streptomyces coelicolor. |
| AID567567 | Antimicrobial activity against Bacillus sp. BS-01 expressing multiple resistance gene cfr and phenolic resistance gene fexA obtained from swine feces | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces. |
| AID519156 | Tmax in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID520732 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring plasmid LI50 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID542389 | Antimicrobial activity against Staphylococcus aureus RN4220 transformed with Staphylococcus aureus ST9 plasmid pSCFS3 carrying cfr and fexA genes | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. |
| AID585427 | Antimicrobial activity against oqxAB positive Escherichia coli C600 XT11-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID585431 | Antimicrobial activity against oqxAB positive Escherichia coli C600 D83-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID519149 | Mean residence time in pigeon at 30 mg/kg, iv by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572798 | Antimicrobial activity against marR-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585419 | Antimicrobial activity against oqxAB positive Escherichia coli C600 W281-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID541855 | Antimicrobial activity against Escherichia coli ATCC 29522 by microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri. |
| AID519175 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 in pigeon assessed as decrease in level of bacteria in fecal shedding between 5 to 13 days post inoculation relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID542387 | Antimicrobial activity against Staphylococcus aureus RN4220 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. |
| AID572596 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 102SA00 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID567568 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring pBS-01multiple resistance gene cfr and phenolic resistance gene fexA obtained from swine feces | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces. |
| AID543234 | Antibacterial activity against multidrug-resistant Salmonella enterica subsp. enterica serovar Typhimurium BN9181 expressing floR | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Truncated tni module adjacent to the complex integron of salmonella genomic island 1 in Salmonella enterica serovar Virchow. |
| AID572593 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 902SA92 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572796 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID520744 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CM05 assessed as modification of A2058 site in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID520737 | Antimicrobial activity against Staphylococcus aureus RN4220 harboring erm(B) promoter-deficient plasmid MS2 by disk diffusion assay | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID531641 | Antimicrobial activity against Enterococcus faecalis ATCC 29212 | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID572807 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519153 | AUC (0 to infinity) in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID519174 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 in pigeon spleen assessed as decrease in bacterial count relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID584114 | Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID584115 | Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12 | LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus. |
| AID572595 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 902SA92 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572804 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572793 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9181 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID543235 | Antibacterial activity against multidrug-resistant Salmonella enterica serovar Virchow B94 expressing floR2 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Truncated tni module adjacent to the complex integron of salmonella genomic island 1 in Salmonella enterica serovar Virchow. |
| AID531643 | Antimicrobial activity against linezolid-resistant Enterococcus faecium A6349 expressing VanA gene | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID519168 | Plasma protein binding in pigeon at 10 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID519166 | Plasma protein binding in pigeon at 2.5 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572598 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium 102SA00 harboring GyrA S83A and D87N, GyrB S464F and ParC S80I mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519173 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 in pigeon kidney assessed as decrease in bacterial count relative to untreated control | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID585418 | Antimicrobial activity against Escherichia coli C600 by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID520734 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus CM05 by broth microdilution method | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID519152 | Half life at beta phase in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID531640 | Antimicrobial activity against linezolid-,erythromycin-resistant Staphylococcus aureus A7820 with G2576U mutation at 23s rRNA | 2008 | Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10 | R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance. |
| AID519163 | AUC (0 to infinity) in pigeon at 30 mg/kg, po | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID541856 | Antimicrobial activity against florfenicol-resistant Edwardsiella ictaluri M07-1 by microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri. |
| AID585422 | Antimicrobial activity against oqxAB positive Escherichia coli C600 W245-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID572787 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 543SA98 harboring GyrA S83F mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572816 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN18/71 harboring plasmid encoded RamR gene, GyrA G81C,acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585423 | Antimicrobial activity against oqxAB positive Escherichia coli C600 G262-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID541857 | Antimicrobial activity against Escherichia coli ATCC 29522 carrying Edwardsiella ictaluri pM07-1 by microdilution assay | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri. |
| AID660265 | Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump | 2012 | European journal of medicinal chemistry, Jun, Volume: 52 | Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics. |
| AID585421 | Antimicrobial activity against oqxAB positive Escherichia coli C600 W322-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID519167 | Plasma protein binding in pigeon at 0.5 ug/ml | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572794 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9181 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID1879067 | Antibacterial activity against pET28a-NDM-1 positive Escherichia coli BL21(DE3) isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli. |
| AID572801 | Antimicrobial activity against soxS::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID541858 | Fold resistance, ratio of MIC for florfenicol-resistance Edwardsiella ictaluri M07-1 to MIC for florfenicol-susceptible Edwardsiella ictaluri | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | IncA/C plasmid-mediated florfenicol resistance in the catfish pathogen Edwardsiella ictaluri. |
| AID519148 | Volume of distribution in pigeon at 30 mg/kg, iv by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID567569 | Antimicrobial activity against Staphylococcus aureus RN4220 | 2010 | Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9 | First report of the multidrug resistance gene cfr and the phenicol resistance gene fexA in a Bacillus strain from swine feces. |
| AID543236 | Antibacterial activity against multidrug-resistant Salmonella enterica serovar Virchow B98 expressing floR2 | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Truncated tni module adjacent to the complex integron of salmonella genomic island 1 in Salmonella enterica serovar Virchow. |
| AID572802 | Antimicrobial activity against Salmonella enterica serovar Typhimurium S/921495 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572799 | Antimicrobial activity against marA::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572791 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9945 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID585432 | Antimicrobial activity against oqxAB positive Escherichia coli DH5[alpha] harboring pMD18-T::oqxAB by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID572811 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18/41 harboring GyrA G81C,acrR mutant genes by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572806 | Antimicrobial activity against Salmonella enterica serovar Typhimurium BN18 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572792 | Antimicrobial activity against ramA::kan-deficient Salmonella enterica serovar Typhimurium BN9945 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID520742 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus RN4220 harboring erm(B) and cfr gene assessed as modification of A2058 site in 23S rRNA | 2008 | Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5 | Transcriptional and translational control of the mlr operon, which confers resistance to seven classes of protein synthesis inhibitors. |
| AID542385 | Antimicrobial activity against methicillin-resistant Staphylococcus aureus ST398 expressing cfr, fexA, erm(A), tet(M) and mecA genes | 2009 | Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2 | Methicillin-resistant and -susceptible Staphylococcus aureus strains of clonal lineages ST398 and ST9 from swine carry the multidrug resistance gene cfr. |
| AID519172 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 at 4 ug/ml after 16 hrs | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID1879068 | Antibacterial activity against NDM-1 positive Escherichia coli ZC-YN3 isolates assessed as inhibition of bacterial growth incubated for 18 to 24 hrs by CLSI based broth microdilution method | 2022 | European journal of medicinal chemistry, Mar-05, Volume: 231 | Metallo-β-lactamases inhibitor fisetin attenuates meropenem resistance in NDM-1-producing Escherichia coli. |
| AID572797 | Antimicrobial activity against marR::kan-deficient Salmonella enterica serovar Typhimurium S/921495 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572803 | Antimicrobial activity against ramR-deficient Salmonella enterica serovar Typhimurium S/921495 harboring plasmid encoded RamR gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572788 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium 543SA98 harboring plasmid encoded RamR gene, GyrA S83Y mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519169 | Antimicrobial activity against Salmonella enterica subsp. enterica serovar Typhimurium PT99/DAB69 in pigeon macrophage assessed as decrease in bacterial count at 32 ug/ml after 16 hrs | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID572600 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN10055 harboring plasmid encoded RamR gene, GyrA S83Y mutant gene by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID572790 | Antimicrobial activity against multidrug-resistant Salmonella enterica serovar Typhimurium BN9945 by agar doubling dilution method | 2008 | Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7 | ramR mutations involved in efflux-mediated multidrug resistance in Salmonella enterica serovar Typhimurium. |
| AID519154 | Oral bioavailability in pigeon at 30 mg/kg, po by naive pooling approach | 2008 | Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3 | Induction of the carrier state in pigeons infected with Salmonella enterica subspecies enterica serovar typhimurium PT99 by treatment with florfenicol: a matter of pharmacokinetics. |
| AID585426 | Antimicrobial activity against oqxAB positive Escherichia coli C600 X1B1-T transconjugant by CLSI agar dilution method | 2010 | Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10 | Prevalence and dissemination of oqxAB in Escherichia coli isolates from animals, farmworkers, and the environment. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (1.16) | 18.7374 |
| 1990's | 23 (3.81) | 18.2507 |
| 2000's | 129 (21.36) | 29.6817 |
| 2010's | 285 (47.19) | 24.3611 |
| 2020's | 160 (26.49) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (65.66) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 70 (11.15%) | 5.53% |
| Reviews | 5 (0.80%) | 6.00% |
| Case Studies | 5 (0.80%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 548 (87.26%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||